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ABSTRACT
Parathyroid hormone (PTH) is an essential regulator of endochondral bone formation and an important anabolic agent for the reversal of bone
loss. PTH mediates its functions in part by regulating binding of the bone-related activating transcription factor 4 (ATF4) to the osteoblast-
speciﬁc gene, osteocalcin. The basic helix-loop-helix (bHLH) factors Twist1 and Twist2 also regulate osteocalcin transcription in part through
the interaction of the C-terminal ‘‘box’’ domain in these factors and Runx2. In this study, we discovered a novel function of PTH: its ability to
dramatically decrease Twist1 transcription. Since ATF4 is a major regulator of the PTH response in osteoblasts, we assessed the mutual
regulation between these factors and determined that Twist proteins and ATF4 physically interact in a manner that affects ATF4 DNA binding
function. We mapped the interaction domain of Twist proteins to the C-terminal ‘‘box’’ domain and of ATF4, to the N-terminus. Furthermore,
we demonstrate that Twist1 overexpression in osteoblasts attenuates ATF4 binding to the osteocalcin promoter in response to PTH. This
study thus identiﬁes Twist proteins as novel inhibitory binding partners of ATF4 and explores the functional signiﬁcance of this interaction.
J. Cell. Biochem. 113: 70–79, 2012.  2011 Wiley Periodicals, Inc.
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P arathyroid hormone (PTH) is a major mediator of boneremodeling and an essential regulator of calcium homeosta-
sis. Inappropriate production of PTH or the PTH-related peptide
(PTHrP) accounts for the majority of causes of hypercalcemia. PPR
(aka PTH-1R), the receptor for PTH and PTHrP, is expressed on
osteoblasts and is a member of the superfamily of receptors coupled
to guanyl nucleotide-binding regulatory G proteins. This receptor
which signals through at least two second messenger systems,
adenylate cyclase, and phospholipase C, can be activated in a similar
manner by the amino-terminal fragments of PTH and PTHrP
[Gardella and Potts, 2008]. Depending on its mode of administration,
PTH can have either catabolic or anabolic effects on bone. The
anabolic actions have been attributed to increased proliferation of
osteoprogenitor cells and osteoblasts [Miao et al., 2002; Datta et al.,
2007; Pettway et al., 2008], decreased osteoblast apoptosis [Jilka
et al., 1999; Chen et al., 2002; Bellido et al., 2003], and/or increased
osteoblast differentiation [Yu et al., 2009].
Important insights into mechanisms controlling osteoblast-
speciﬁc gene expression have been gained through the study of
regulatory sequences in the osteoblast-speciﬁc gene, osteocalcin.
The mouse genome contains two osteocalcin genes, mOG1 and
mOG2, having identical patterns of expression and very similar
promoter sequences [Ducy and Karsenty, 1995]. ThemOG2 promoter
contains an OSE1motif (osteocalcin-speciﬁc element 1; TTACATCA)
and two OSE2 motifs (AACCACA) within its ﬁrst 657 bp [Ducy and
Karsenty, 1995]. Both motifs are required for osteoblast-speciﬁc
expression of osteocalcin in vitro and in vivo [Ducy and Karsenty,
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been identiﬁed as a DNA binding site for the transcription factor
ATF4, also known as CREB2 (cAMP-response element-binding
protein 2). ATF4 is a basic leucine-zipper transcription factor that is
a member of the ATF/CREB protein family.
The crucial role for ATF4 in osteoblast differentiation and bone
development was demonstrated using Atf4-deﬁcient mice [Yang
et al., 2004b], which exhibit a marked reduction or delay in
mineralization of several bones including frontal and parietal bones,
clavicles, and long bones. At birth, the delay of mineralization in
the skull was still present as demonstrated by widening of the
fontanelles. Postnatally,Atf4-deﬁcient mice have a severe reduction
in bone volume and in the number and thickness of trabeculae that
persists throughout life. ATF4 is required for PTH induction of
osteocalcin gene expression in osteoblasts [Yu et al., 2008]. PTH
accomplishes this in part by increasing ATF4 mRNA and protein
level as well as increasing ATF4 binding to OSE1 DNA. Recently,
results from our group demonstrated that ATF4 plays a critical role
in the anabolic effects of PTH on bone [Yu et al., 2009].
The OSE2 site of the osteocalcin promoter binds Runx2, a
runt domain-containing transcription factor that is essential
for osteoblast and hypertrophic chondrocyte differentiation and
bone formation during embryogenesis and postnatal life. Runx2
haploinsufﬁciency causes cleidocranial dysplasia, a disorder
characterized by defective endochondral and intramembranous
bone formation [Mundlos et al., 1997]. Runx2/ mice die at birth
and lack skeletal ossiﬁcation and mature osteoblasts [Komori et al.,
1997; Mundlos et al., 1997]. During early development, Runx2
is essential for osteoblast differentiation [Ducy et al., 1997]. In
terminally differentiated osteoblasts, Runx2 regulates the expres-
sion of bone matrix proteins [Ducy et al., 1999]. Runx2 and ATF4
cooperatively regulate osteocalcin transcription through interac-
tions with OSE1 and OSE2 sites in the promoter since mutation
of OSE1 markedly reduced Runx2-dependent mOG2 transcription
and mutation of either OSE1 or OSE2 dramatically reduced ATF4-
stimulated activity [Xiao et al., 2005].
Recent studies identiﬁed the basic helix-loop-helix (bHLH)-
containing transcription factors, Twist1 and Twist2, as major
regulators of Runx2 function. Twist1 is required for closure of the
neural tube during mouse development [Chen and Behringer, 1995];
mice homozygous for a Twist2 null allele show elevated expression
of proinﬂammatory cytokines causing perinatal death [Sosic et al.,
2003]. Twist proteins transiently inhibit osteoblast differentiation
during skeletogenesis through the interaction of a novel domain in
these proteins called the Twist box and the Runx2 DNA binding
domain [Bialek et al., 2004]. A more recent study suggested that, in
addition to the C-terminus Twist box, the bHLH domain of Twist1
also plays a signiﬁcant role in regulating Runx2 function
[Connerney et al., 2006]. In addition, the bHLH domain of Twist1
mediates homo- and heterodimerization with other bHLH family
members such that small changes in the level of Twist1 expression
alter the ratio of homodimers to heterodimers, which can have
dramatic effects on transcriptional regulation.
It was hypothesized that PTH is able to affect osteoblast
differentiation by regulating Twist1. We demonstrate that PTH
has a profound inhibitory effect on Twist1 mRNA in MC3T3-E1
osteoblasts. Since ATF4 is a major regulator of the PTH response in
osteoblasts, studies were extended to explore the interaction
between Twist1 and ATF4. As will be shown, Twist proteins inhibit
ATF4 binding to OSE1 in part by directly binding to ATF4. This
study thus identiﬁes Twist proteins as novel inhibitory binding




Tissue culture medium and fetal bovine serum were obtained from
Invitrogen (Carlsbad, CA). PTH (1-34, human) was obtained from
Bachem (Torrance, CA).
CELL CULTURE AND CELLULAR TRANSFECTIONS
MC3T3-E1 Subclone 14 cells which exhibit high levels of osteoblast
differentiation and mineralization after growth in medium contain-
ing ascorbic acid were plated in a-MEM with 10% fetal bovine
serum containing 100U/ml penicillin and 100mg/ml streptomycin
at a density of 50,000 cells/cm2. After 24 h, cells were cultured in
medium containing 0.1% FBS in the presence or absence of 108M
PTH for 6 h. Cultures at passage less than 15 were used for all
experiments.
ROS 17/2.8 osteosarcoma cells and 293T human kidney epithelial
cells (HEK293T) were cultured in Dulbecco’s modiﬁed Eagle’s
medium containing 10% fetal bovine serum (Invitrogen) and
50 IU/ml penicillin–streptomycin (Mediatech, Herndon, VA). 293T
cells were transfected using 25-kDa linear polyethylenimine
(Polysciences, Warrington, PA) as described previously [Danciu
and Whitman, 2010].
ROS 17/2.8 transfection was performed as follows. Cells were
plated at a density of 3 106 cells per 10 cm dish in antibiotic-free
medium. Twenty-four hours post plating, cells were transfected
using 8.7mg of pcs4-3ﬂag-mTwist1 DNA, 21.75ml Lipofectamine
LTX and 8.7ml PLUS reagent (Invitrogen). Forty-eight hours post
transfection, cells were stimulated with vehicle or 107M PTH for
6 h in complete media.
DNA CONSTRUCTS
p4OSE1-luc was previously described [Ducy and Karsenty, 1995]. To
generate mouse ATF4, we performed PCR with primers containing
BglII or XhoI sites using pCMV/ATF4 as template [Yang et al.,
2004b]. mATF4 was then subcloned at the BglII/XhoI site of pcs4-
3Flag. Plasmids expressing truncated forms of ATF4 (aa 1–333 and
aa 1–276) were generated in a similar manner using templates as
described previously [Xiao et al., 2005]. One-step site-directed PCR-
based mutagenesis was performed using pcs4-3Flag-mATF4 as
previously described to generate the following mATF4 deletion
mutants: D1–90, D91–211, D1–211, D211–276, D1–276 [Makarova
et al., 2000]. Mouse Twist1 constructs were generated in our
laboratory as previously described [Danciu and Whitman, 2010].
Full-length GST-ATF4 fusion protein expression plasmid was
constructed by subcloning the full-length ATF4 cDNA into the GST
gene fusion vector pGEX-4T-1 (GE Heathcare Bio-Sciences Corp,
Piscataway, NJ) in correct reading frame as previously described
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[Xiao et al., 2005]. Full-length HIS-HA-Twist1 was a kind gift of Dr.
Gerard Karsenty (Columbia University, NY; [Bialek et al., 2004])
A construct containing full-length human Twist2 was obtained
from the Harvard Institute of Proteomics and subcloned using PCR
primers containing BglII and EcoRI sites in the pcs4-3Flag vector.
One-step site-directed PCR-based mutagenesis was performed using
pcs4-3Flag-hTwist2 as a template as described above. All sequences
were veriﬁed by automatic DNA sequencing.
QUANTITATIVE RT-PCR
MC3T3-E1 osteoblasts were plated at a density of 50,000 cells/cm2 in
35mm dishes and cultured in 10% FBS overnight. Cells were then
treated with 108M PTH for 6 h in 0.1% FBS. RNA was isolated and
puriﬁed using an RNeasy Mini Kit (Qiagen, Inc., Valencia, CA).
Double-stranded complementary DNA (cDNA) was synthesized from
1mg of RNA, using Oligo d(T) (Applied Biosystems, Foster City, CA)
to prime total RNA samples for reverse transcription using
Multiscribe reverse transcriptase (Applied Biosystems). The TaqMan
universal PCR master mix (Applied Biosystems) was used for
detection of cDNA. cDNA was ampliﬁed using customized primers
and probes (Applied Biosystems). Rodent glyceraldehyde-3-phos-
phate dehydrogenase (GAPDH) was used as an endogenous control.
Ampliﬁcation of cDNA was performed using the ABI Prism 7700
Sequence Detection System (Applied Biosystems). Relative quanti-
ﬁcation of data generated using this systemwas performed using the
standard curve method. Experiments were performed three times
with similar results.
LUCIFERASE ASSAYS
p657mOG2-luc, p4OSE1-luc and p657mOG2OSE2mt-luc, which
contains 2-bp substitution mutations in the two OSE2 sites at
positions 135/134 and 606/605 (CCAAGAACA), respective-
ly, were previously described [Xiao et al., 2005]. MC3T3-E1
containing stably integrated copies of a 1.3-kb mOG2 promoter
driving a ﬁreﬂy luciferase reporter gene has been previously
described by our group [Jiang et al., 2004]. 293T cells were plated in
24 well plates at a density of 2.4 105 cells/well and transfected on
the same day using PEI as described above with 60 ng p4OSE1-luc,
60 ng pcs4-3HA-mATF4, 60 ng CMV/b-galactosidase (to control for
transfection efﬁciency) and either 60, 120, or 240 ng pcs4-3Flag-
mTwist1 or 120 ng pcs4-Twist1-box (mTwist1 missing the C-
terminus Twist box). Cells were harvested 48 h after transfection and
assayed using a Dual Luciferase assay kit (Promega, Madison, WI) on
a Monolight 2010 luminometer (BD Biosciences, Bedford, MA).
Luciferase assays using MC3T3 osteoblasts were performed as
follows. Cells were plated at a density of 50,000 cells/cm2 in six well
dishes 24 h prior to transfection using Lipofectamine LTX
(Invitrogen) and 3mg of p4OSE1-luc and 0.75mg of CMV/b-
galactosidase. Forty-eight hours after transfection, cells were
stimulated with 108M PTH inmedium containing 0.1% FBS for 6 h.
RECOMBINANT PROTEINS AND PULL-DOWN ASSAYS
GST-fusion proteins were isolated from bacterial lysate using
glutathione beads, and His-tagged proteins were isolated from
bacterial lysate using the Talon system (Clontech) according to
manufacturers’ directions. Puriﬁed GST was a kind gift of Dr. Jorge
Iniguez-Llhui (University of Michigan, MI). For the pull-down,
200ml of 50% sepharose bead slurry 16mg of puriﬁed GST or GST-
ATF4 were incubated for 1 h at 48C. Puriﬁed His-HA-Twist1 protein
was precleared using sepharose beads for 1 h at 48C. Precleared
Twist1 protein was then incubated with 20ml of sepharose-GST or
sepharose-GST-ATF4 for 1 h at 48C. Five 10min washes were
performed at 48C as follows: washes 1, 4, 5: 0.1% NP40 in PBS;
washes 2, 3: 500mM NaCl, 0.1% NP40 in PBS.
WESTERN BLOT ANALYSIS AND IMMUNOPRECIPITATIONS
Cultured 293T cells were rinsed twice in ice-cold phosphate-
buffered saline then lysed in modiﬁed RIPA buffer [(150mM NaCl,
50mM Tris (pH 8), 25mM b-glycerophosphate, 100mM sodium
ﬂuoride, 2mM sodium orthovanadate, 10mM sodium pyrophos-
phate, 2 Complete EDTA-free protease inhibitor mixture (Roche
Applied Science, Indianapolis, IN), 1mM phenylmethylsulfonyl
ﬂuoride), 2mM EDTA, 1% Nonidet P-40 (NP-40)]. Lysates were
centrifuged and supernatants collected.
Immunoprecipitations were performed using an anti-Flag matrix
(Sigma-Aldrich, St. Louis, MO) for 3 h at 48C with gentle rocking.
Proteins were electrophoretically separated on polyacrylamide gels
and then transferred onto nitrocellulose membranes. The following
antibodies were used for Western blotting: anti-HA-peroxidase rat
monoclonal peroxidase-conjugated antibody (clone 3F10; Roche),
anti-Flag-peroxidase mouse monoclonal peroxidase-conjugated
antibody (Sigma), and anti-actin mouse monoclonal antibody
(Sigma). Rabbit anti-mouse ATF4 antibody for immunoprecipitation
and Western blotting was from Santa Cruz Biotechnology (Santa
Cruz, CA). Anti-Flag HRP antibody was from Sigma. Horseradish
peroxidase-conjugated goat anti-rabbit or -mouse IgG were from
Jackson Immunolabs (West Grove, PA).
Nuclear and cytoplasmic fractions were obtained using the NE-
PER extraction kit from Thermo Scientiﬁc (Rockford, IL) according
to the manufacturer’s directions. Histone3 antibody was obtained
form Cell Signaling Technology (Danvers, MA).
CHROMATIN IMMUNOPRECIPITATION
Chromatin immunoprecipitation (ChIP) was performed as previously
described [Li et al., 2010]. Brieﬂy, ROS 17/2.8 cells transfected with
pcs4-3ﬂag-mTwist1 or empty vector as described above, were cross-
linked with 1% formaldehyde and sonicated in sonication buffer.
The sheared chromatin was then precipitated with ATF4 antibody
(Santa Cruz Biotechnology) or control IgG (anti-rabbit). The
immunoprecipited chromatin library was measured by PCR with
the following primers: 50-GCAGTCACCAACCACAGCATCCTT-30
(forward) and 50-TCCACTGCCTGAGCCCCTAATGT-30 (reverse).
These primers were based on the rat osteocalcin gene sequence
ﬂanking a previously identiﬁed ATF1 site [Ducy and Karsenty,
1995]. The coding region primers were previously published by our
group [Li et al., 2010]. ChIP PCR products were visualized on 2.5%
agarose gel and stained with ethidium bromide. Puriﬁed input
chromatin was used to perform parallel PCR with the respective
primer pairs.
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STATISTICAL ANALYSIS
The differences among groups for the effect of Twist1 on
ATF4-mediated OSE1 transcriptional regulation (Fig. 2A) were
statistically assessed by one-way analysis of variation (ANOVA)
with Tukey multiple comparison post hoc test using a statistical
software package (GraphPad Prism version 4.00, GraphPad
Software, San Diego, California). The differences between groups
for the effect of PTH stimulation on OSE1-luciferase activity
(Fig. 1A) were statistically assessed by a one-sided Student’s
t-test; the differences between groups for PTH-mediated Twist1
regulation as assessed by quantitative PCR were assessed using
the Bonferroni test (PASWStatistics 18.0, SPSS Inc., Chicago, IL;
Fig. 1B).
RESULTS
PTH DECREASES Twist1 EXPRESSION IN OSTEOBLASTS
The observation that Runx2 is expressed in the lateral plate
mesoderm at E10 during mouse development [Ducy, 2000] yet
expression of molecular markers of differentiated osteoblasts cannot
be detected prior to E13 [Bialek et al., 2004], led to the identiﬁcation
of Twist proteins as essential regulators of osteoblast differentiation.
Twist proteins do not affect Runx2 expression yet they are able to
down-regulate osteocalcin, an osteoblast-speciﬁc gene whose
expression is under Runx2 control [Bialek et al., 2004]. Because
the osteocalcin gene is also regulated by PTH [Boudreaux and
Towler, 1996; Yu and Chandrasekhar, 1997], we investigated the
effect of PTH stimulation on osteoblast Twist1 transcription. Our
group has previously published that the PTH/PTHrP receptor (PPR),
plays an important role in the process of proliferation and
differentiation of mesenchymal cells into osteoblasts [McCauley
et al., 1995; Chen et al., 2002]. Furthermore, our group also has
shown that a 6 h stimulation of MC3T3 osteoblasts with 108M PTH
resulted in a signiﬁcant upregulation of osteocalcin mRNA [Jiang
et al., 2004]. Following an identical stimulation protocol, we
observed at 6 h an approximately 60% reduction in Twist1 mRNA as
assessed by real-time RT-PCR and illustrated in Figure 1A. PTH
mediates its action on osteocalcin gene expression in part by
increasing ATF4 expression and activity in osteoblasts [Jiang et al.,
2004]. ATF4 activates osteocalcin transcription through direct
binding to the OSE1 site in addition to interactions with Runx2 at the
OSE1 and OSE2 sites [Ducy and Karsenty, 1995; Xiao et al., 2005].
We previously demonstrated that an artiﬁcial promoter containing
four copies of OSE1 fused to a34 toþ13 minimal mOG2 promoter
(p4OSE1-luc) was also stimulated by ATF4 in osteoblasts, while the
same construct containing mutated OSE1 was not [Xiao et al., 2005].
We conﬁrmed that in our system, 6 h of PTH stimulation increased
ATF4-dependent transcriptional activity in MC3T3 osteoblasts
(Fig. 1B). Furthermore, following an identical stimulation protocol,
we extended our observations to include osteocalcin promoter
regulation results. Two osteocalcin promoter regions were tested as
follows (Fig. 1C, left and right panels). The 657-bp mOG2 promoter
contains a single ATF4-binding site (OSE1) at 48/55 and two
Runx2-binding sites (OSE2) at 131/137 and 602/608. Our
group has previously demonstrated that mutating both OSE2 sites
completely abolishes the Runx2-dependent induction of promoter
activity [Xiao et al., 2005]. PTH-activation of the osteocalcin
promoter containing mutant OSE2 sites, demonstrates that Runx2
activity (and therefore Twist1 modulation of Runx2 activity) is
dispensable for this response. In addition, we used MC3T3-E1 cells
containing stably integrated copies of a 1.3-kb mOG2 promoter
driving a ﬁreﬂy luciferase reporter gene. In both instances, a 6-h
stimulation with 108M PTH resulted in a signiﬁcant activation of
osteocalcin transcription. These ﬁndings demonstrate that, in our
system, PTH decreases Twist1 expression while simultaneously
activating osteocalcin transcription.
Fig. 1. PTH effects on MC3T3-E1 osteoblasts. Cells were seeded at a density
of 50,000 cells/cm2 in 35mm dishes and cultured in 10% FBS for 24 h prior to
stimulation with 108M PTH for 6 h in 0.1% FBS. A: PTH stimulation of
MC3T3 osteoblasts causes a signiﬁcant decrease in Twist mRNA. RNA prepa-
ration and quantitative real-time RT-PCR for Twist1 was performed and
normalized to GAPDH mRNA. Data represent mean SD expressed as fold
over control. B: PTH increases ATF4-dependent transcriptional activity in
MC3T3-E1 osteoblasts. Cells were transiently transfected with p4OSE-1-luc
and b-galactosidase normalization plasmid and treated for 6 h with 108M
PTH in 0.1% FBS. Experiments were repeated at least three times in triplicates.
P< 0.0001 (control vs. PTH). C: PTH activates the osteocalcin promoter in
MC3T3-E1 osteoblasts. Left panel, cells were transiently transfected with wild-
type and mutant p657mOG2-luc (mutations of both OSE2 sites which
abolishes the Runx2-dependent induction of promoter activity) and b-galac-
tosidase normalization plasmid and stimulated 48 h post transfection for 6 h
with 108M PTH in 0.1% FBS. Experiments were repeated at least three times
in replicates. P< 0.001 (control vs. PTH). Right panel, MC3T3-E1 containing
stably integrated copies of a 1.3-kb mOG2 promoter driving a ﬁreﬂy luciferase
reporter gene were cultured in 10% FBS for 24 h prior to stimulation
with 108M PTH for 6 h in 0.1% FBS. Luciferase activity was normalized
to total protein. Experiments were repeated at least three times in replicates.
P< 0.001 (control vs. PTH).
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Twist1 INHIBITS ATF4 TRANSCRIPTIONAL ACTIVITY
Previous time-course experiments in osteoblasts demonstrated that
PTH induction of Atf4 occurs within 1 hr of PTH addition and peaks
after 3–6 h [Yu et al., 2008]. Since PTH increases Atf4 transcription
and binding activity and also represses Twist1 transcription over a
similar time-course, we hypothesized that Twist1 down-regulation
by PTH may be able to further enhance the ATF4 response similar to
the way Twist1 downregulation permits cranial suture development
by relieving inhibition of Runx2 during development [Bialek et al.,
2004]. Therefore, the role of Twist1 in ATF4 regulation of the OSE1
site in the osteocalcin promoter was investigated. As shown in
Figure 2A, ATF4 activated p4OSE1-luc and Twist1 was able to
inhibit this response in a dose-dependent manner. Furthermore, a
Twist1 construct missing the C-terminal domain called ‘‘the Twist
box’’ [Bialek et al., 2004] was not able to inhibit ATF4-dependent
activation of the luciferase construct. Since the reduction in
p4OSE1-luc activity could be due to Twist1 causing a decrease in
ATF4 levels, we determined endogenous ATF protein level in ROS
osteoblast-like cells overexpressing Twist1. Twist1 overexpression
did not affect ATF4 protein levels (Fig. 2B, left panel). Figure 2B,
right panel, demonstrates that overexpressed Twist1 localizes
mainly in the nucleus where it is able to interact with ATF4 which
is also a nuclear protein.
These results suggest that Twist1 inhibits ATF4 function through
mechanisms independent of ATF4 protein level.
PROTEIN–PROTEIN INTERACTION STUDIES REVEAL A DIRECT
INTERACTION BETWEEN ATF4 AND THE C-TERMINAL
DOMAIN OF Twist1
To identify the domains within Twist proteins responsible for the
inhibition of ATF4 function, we used Twist1 deletion mutants in
DNA cotransfection assays. The following Twist1 and Twist2
constructs were used: full-length, N-term (containing the N-
terminus only), Nþ box (missing the bHLH domain), and box
(missing the Twist box) [Bialek et al., 2004]. Figure 3A,B illustrate
that both Twist1 and Twist2 interact with ATF4. When Twist
constructs missing the bHLH domain were used, the interaction was
Fig. 2. Twist1 decreases ATF4-dependent transcriptional activity without
affecting ATF4 levels. A: Twist-dependent ATF4 transcriptional regulation in
293T cells—response is dependent upon the C-terminus Twist1 box. Cells were
plated in 24 well plates and transiently transfected with 60 ng p4OSE1-luc,
60 ng pcs4-3HA-mATF4, various concentrations of pcs4-3Flag-mTwist1 rang-
ing from 60 to 240 ng as indicated, 120 ng pcs4-3Flag-(mTwist1-box) and
60 ng b-galactosidase normalization plasmid. Cells were harvested and assayed
for dual-luciferase activity 48 h after transfection. Fireﬂy luciferase activity
was normalized to b-galactosidase activity (for transfection efﬁciency). Data
represent mean SD. Experiments were repeated at least three times and
qualitatively identical results were obtained. P< 0.001. B: Left panel, Twist1
overexpression in ROS 17/2.8 osteoblast-like cells does not affect endogenous
ATF4 levels. Cells transfected with vector only (pcs4-3Flag) or with Flag-
tagged Twist1 were collected 48 h post transfection and processed for Western
blotting using the indicated antibodies. Right panel, A signiﬁcant portion of
overexpressed Twist1 protein localizes in the nucleus as does ATF4.
Fig. 3. ATF4 and Twist interact directly—mapping of the domains necessary for this interaction. A: Twist C-terminal box domain is necessary and sufﬁcient for Twist1 and
Twist2 interaction with ATF4. 293T cells were transfected with the following constructs in pcs4-3Flag vector: mTwist1, Twist1 N-term (mTwist1 containing the N-terminus
only), Twist1 Nþ box (mTwist1 missing the bHLH domain), Twist1-box (mTwist1 missing the C-terminus Twist box); similar constructs were generated using Twist2. Cells were
also transfected with an equal amounts of pcs4-3HA-mATF4 as indicated. Upper panels are of the ﬂag immunoprecipitations blotted with anti-HA antibody or with an anti-Flag
antibody to detect ATF4 or Twist, respectively. An anti-HA Western blot of whole lysates indicates that ATF4 level was decreased in the presence of Twist1 or Twist2 N-term.
B: ATF4 does not interact with Twist1 N-term (which does not have the bHLH and the box domains). 293T cells were transfected with either 0.5mg (denoted as ‘‘1’’) or 1.5mg
(denoted as ‘‘2’’) of pcs4-3HA-mATF4 in the presence or absence of 0.5mg WT or mutant (Twist1 N-term) pcs4-3Flag-mTwist1. Flag immunoprecipitations were blotted with
an anti-HA antibody to detect ATF4; total lysates were blotted with anti-HA and anti-Flag antibodies to detect ATF4 and Twist1 levels, respectively. C: Twist1 interacts with aa
1-276 of ATF4. 293T cells were transfected with pcs4-3Flag-mTwist1 and an equal amount of pcs4-3HA-mATF4 or D1-276mATF4 (mutant missing aa 1-276). Flag
immunoprecipitations were blotted with an anti-HA antibody to detect ATF4; total lysates were blotted with anti-HA and anti-Flag antibodies to detect ATF4 and Twist1 levels,
respectively. D,E: Twist1 interacts with various ATF4 mutants containing partial deletions of aa 1-276. 293T cells were transfected with 0.5mg pcs4-3Flag-mTwist1 and an
equal amount of pcs4-3HA-mATF4 or the various ATF4 mutants (D1–90: missing the ﬁrst 90 aa; D91–211: missing aa 91–211; D211–276: missing aa 211–276). F: Due to
the lower levels of total ATF4 protein observed when theD1–90mutant was used, two different concentrations of pcs4-3HA-D-90ATF4 were used: 0.5 and 1.5mg as illustrated
in the lower right panel. Lower left panel also demonstrates that aa 91–276 are dispensable for Twist1 interaction. For all panels, Flag immunoprecipitations were blotted with
an anti-HA antibody to detect ATF4; total lysates were blotted with anti-HA and anti-Flag antibodies to detect ATF4 and Twist1 levels, respectively. G: The bZIP and
the carboxy-terminal domains of ATF4 are dispensable for Twist1 interaction. 293T cells were transfected with pcs4-3Flag-mTwist1 and an equal amount of pcs4-3HA-mATF4,
1-276mATF4 (mutant containing a stop codon after aa 276), or 1-333mATF4 (mutant containing a stop codon after aa 333). Flag immunoprecipitations were blotted with an
anti-HA antibody to detect ATF4; total lysates were blotted with anti-HA and anti-Flag antibodies to detect ATF4 and Twist1 levels, respectively. H: Twist1 and ATF4 interact
directly (pull-down assays). GST-ATF4 or GST alone complexed to glutathione beads were incubated with His-HA-Twist-1. Eluates from the beads were immunoblotted with
anti-HA antibody to detect Twist1 and ATF4 antibody. Only GST-ATF4 and His-Twist1 showed direct interaction. Lower panels show equal loading of GST-ATF4 and GST as
indicated by Coomassie staining of the gel.
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Fig. 3.
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present but reduced. Twist constructs containing only the N-
terminus as well as Twist constructs missing the Twist box failed to
interact with ATF4 indicating that the Twist domain necessary for
ATF4 interaction is the Twist box, the same domain necessary for
Runx2 interaction. To further conﬁrm that ATF4 does not interact
with N-term Twist1, we used different concentrations of ATF4 since
ATF4 total protein levels are decreased in the presence of N-term
Twist1. As Figure 3B indicates, N-term Twist1 fails to interact with
ATF4 even at high ATF4 protein levels.
To map the ATF4 domain necessary for the Twist-ATF4
interaction, we overexpressed Flag-tagged Twist1 and various
HA-tagged ATF4 constructs. Total lysates were immunoprecipitated
with an anti-Flag matrix, followed byWestern blot analysis using an
anti-HA antibody. As shown in Figure 3C–F, ATF4 protein was
present in an anti-Twist1 immunoprecipitate. Twist1 was not
immunoprecipitated by anti-ATF4 antibodies in the absence of
ATF4. Figure 3G illustrates that deletion of the basic region and the
whole leucine zipper domain (ATF4 containing the ﬁrst 276 aa) did
not abolish ATF4 interaction with Twist1; the decrease in interaction
reﬂects lower total ATF4 protein level of the 276 (stop) ATF4
construct. An ATF4 construct missing the ﬁrst 211 aa (D1–211) or
the ﬁrst 276 aa (D1–276) is not able to interact with Twist1
suggesting that the ﬁrst 211 aa of ATF4 are necessary for its
interaction with Twist1 (Fig. 3C,D). To characterize this region
further, we used two ATF4 deletion mutants: ATF4 construct
missing the ﬁrst 90 aa (D1–90), and aa 91–211 (D91–211). As
Figure 3D,E illustrate, Twist1 interacts with both deletion mutants of
ATF4. This ﬁnding suggests that while the ﬁrst 211 aa of ATF4 are
necessary for Twist1 interaction, a complex interaction pattern
might occur whereby multiple motifs within this region are involved
in protein–protein interactions. Furthermore, Figure 3G illustrates
that the ATF4 domain interacting with Twist1 is located between aa
1 and 276 and that the basic, ZIP, and the carboxy-terminal domains
are dispensable for this interaction.
To determine whether ATF4 and Twist1 can directly interact in
the absence of other nuclear proteins, we conducted standard GST
pull-down assays using puriﬁed full-length GST-ATF4 and HIS-
Twist1 fusion proteins. Consistent with our immunoprecipitation
results using total cell lysates from cells transfected with ATF4 and
Twist1, puriﬁed HIS-Twist1 was complexed to GST-ATF4 but not to
GST alone (Fig. 3D). The lower panels in Figure 3D are of Coomassie-
stained gel and demonstrate equal levels of GST and GST-ATF4
protein levels.
Twist1 OVEREXPRESSION IN OSTEOBLASTS PREVENTS ATF4
BINDING TO THE OSTEOCALCIN OSE1 SITE IN RESPONSE TO PTH
The ROS cell line derived from a rat osteosarcoma, is a widely used
cell line to study osteoblast-speciﬁc gene expression [Ducy and
Karsenty, 1995]. ROS 17/2.8 cells have markers of both immature
and more differentiated osteoblasts [McCabe et al., 1994] and
most importantly for this study they have highly functional PTH
receptors. Furthermore, these cells do not express Twist1 as assessed
by Northern blotting [Bialek et al., 2004]. To determine the effect of
overexpressed Twist1 on the PTH-induced association of ATF4 with
the endogenous osteocalcin promoter in osteoblasts, we performed
ChIP assays. For this assay we used ROS cells overexpressing Twist1
or vector only, with or without PTH treatment. Figure 2B illustrates
that in these cells, Twist1 overexpression does not affect total ATF4
levels. As shown in Figure 4, ATF4 interacted speciﬁcally with a
chromatin fragment of the proximal osteocalcin promoter that
contains the ATF4-binding site (OSE1); this interaction was
dramatically stimulated by PTH treatment as we previously reported
[Yu et al., 2008]. Moreover, PTH treatment of cells overexpressing
Twist1 did not stimulate ATF4 binding to the OSE1 site in the
osteocalcin promoter supporting our hypothesis that Twist1 is a
negative regulator of ATF4 function.
DISCUSSION
Our ﬁnding that Twist1 interacts directly with ATF4 and that this
interaction inhibits PTH-induced binding of ATF4 to the osteocalcin
promoter, further extends the critical role of Twist1 in regulating
osteoblast function. In addition to increasing osteoblast cell number
Fig. 4. Twist1 overexpression attenuates PTH-induced binding of endoge-
nous ATF4 to the OSE1 site of the osteocalcin promoter in ROS 17/2.8
osteoblast-like cells. ROS cells transfected with pcs4-3ﬂag-mTwist1 or vector
only control (pcs4-3ﬂag) were stimulated with 107M PTH for 6 h as detailed
in Materials and Methods section. A ChIP assay was then performed of the rat
osteocalcin promoter region that contains the ATF-4 binding site OSE1. Two
negative controls were used (ATF4 immunoprecipitate analyzed with coding
region primers and IgG control immunoprecipitate analyzed with promoter
region primers).
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by stimulating osteoblast proliferation and decreasing osteoblast
apoptosis, intermittent PTH also stimulates osteoblast differentia-
tion [Schmidt et al., 1995; Iida-Klein et al., 2002; Wang et al., 2005],
an effect that is in part mediated by ATF4 [Yu et al., 2009]. In vivo,
PTH elevates the expression of genes known to be associated with
osteoblast differentiation including: osteocalcin, bone sialoprotein,
alkaline phosphatase, osteopontin, and osterix. This effect on gene
expression is either reduced or completely abolished in ATF4/
mice [Yu et al., 2009], thus the identiﬁcation of novel regulators of
ATF4 function may provide important insights into the mechanisms
for the anabolic actions of PTH on bone.
Twist proteins have recently been identiﬁed as negative
regulators of osteoblast differentiation. Both Twist1 and Twist2
have a conserved C-terminus domain called the Twist box that
interacts with Runx2 and inhibits the expression of downstream
targets of Runx2 including osteocalcin, an osteoblast-speciﬁc gene
[Bialek et al., 2004]. Osteocalcin transcription is regulated through
OSE1 and OSE2 core sequences in its promoter. Although ATF4
binds to OSE1 and uses this site to activate the osteocalcin promoter
[Yang et al., 2004b], Runx2 is also necessary for this activation as
ATF4 is not able to induce osteocalcin mRNA expression in non-
osteoblastic cells that lack detectable Runx2 [Xiao et al., 2005]. A
further demonstration of this cooperativity between Runx2 and
ATF4 is illustrated by studies in which mutation of either OSE1 or
OSE2 dramatically reduced ATF4-stimulated Runx2 activity [Xiao
et al., 2005]. The relatively rapid decrease of Twist1 mRNA seen after
PTH treatment suggests that, in addition to stimulating ATF4 level
and activity [Yu et al., 2008], PTH promotes transcription by
decreasing Twist1, an inhibitor of both Runx2 and ATF4. In a
manner similar to Twist1 regulation of Runx2, Twist1 inhibits ATF4
function without affecting ATF4 protein levels. bHLH and CREB
family interactions have been previously reported in the context of
muscle and testis development [Muir et al., 2008] where it was
demonstrated that the bHLH domain of scleraxis or paraxis was
sufﬁcient for interaction with the C-terminal region of ATF4.
Although Twist family members were not tested in that study, the
ﬁnding of a bZIP/bHLH interaction is in contrast to ours
demonstrating that the bHLH domain of Twist is dispensable for
ATF4 binding. Paraxis, scleraxis, Twist1 and other bHLH family
members share a high degree of homology in the bHLH domain
[Burgess et al., 1995] so we expected the interaction between Twist1
and ATF4 to also depend on the bZIP/bHLH domains. However, our
data showing that the Nþ box Twist1 (Twist1 mutant missing the
entire bHLH domain) or the corresponding Twist2 mutant interact
with ATF4 clearly demonstrate that the bHLH domain of Twist is not
involved in this interaction. The box domains of Twist1 and Twist2
are highly conserved across species and represent a unique feature
for these two bHLH domain family members. In addition to a direct
interaction between bHLH and CREB/ATF proteins, indirect
interactions mediated by adaptor/linker proteins such as CREB
binding protein (CBP/P300) that have the ability to bind both bHLH
and bZIP domain proteins, have also been demonstrated [Chaudhary
and Skinner, 2001]. Our ﬁnding of an interaction between the box
domain of Twist proteins with a non-bZIP region of ATF4 adds to the
complexity of interactions between these two families of transcrip-
tion factors.
In addition to Runx2, osterix (Osx) is another transcription factor
essential for osteoblast differentiation and bone formation
[Nakashima et al., 2002]. We have shown that intermittent PTH
increases in vivo Osx expression through an ATF4-dependent
pathway [Yu et al., 2009]. Results presented in this study showing
that Twist1 interacts with and inhibits the function of ATF4, suggest
that Twist1 may have broad effects on PTH-mediated osteoblast
differentiation that include Osx in addition to osteocalcin
transcription. ATF4 deﬁciency reduces, but does not completely
block the anabolic actions of PTH. Ovariectomized growing and
adult ATF4/ mice still show a modest increase in bone volume in
response to PTH [Yu et al., 2009] suggesting that other factors in
addition to ATF4 must be involved in the PTH response. In
particular, involvement of Runx2 in the anabolic actions of PTH has
been suggested [Bellido et al., 2003; Krishnan et al., 2003]. Since
Twist is also a negative regulator of Runx2, our studies may have
broader signiﬁcance related to the overall control of osteoblast gene
expression by PTH via Twist inhibition of multiple transcription
factors.
Although it was initially hypothesized that the bHLH domain of
Twist proteins is dispensable for their anti-osteogenic function
[Bialek et al., 2004], recent data reveals a more complex pattern of
osteoblast regulation by these proteins. Studies from the Spicer
laboratory, demonstrated that partner selection of Twist1 has
functional consequences as Twist1 homodimers regulate different
genes compared to Twist1 heterodimers (Twist1/other bHLH protein)
[Connerney et al., 2006]. More importantly, Twist1 requires the
presence of its bHLH family member E2A E12 to inhibit the
differentiation of calvarial cells. Very little is known about how
interactions through the bHLH domain affect C-terminal Twist box
interactions and vice versa; further studies are required to determine
if the Twist1-ATF4 interaction is affected by dimerization through
the HLH domain. Interestingly, we previously demonstrated that
disulﬁde bond formation between Twist1 homodimers signiﬁcantly
reduced its ability to interact with Runx2, indicating that disulﬁde
dimerization in response to an oxidative stress has functional
signiﬁcance [Danciu and Whitman, 2010]. Since Twist1 interaction
with ATF4 is mediated through the same C-terminal domain that is
involved in Runx2 binding, it is likely that oxidative stress as occurs
during prolonged states of inﬂammation, would alter ATF4-
dependent PTH responsiveness of osteoblasts.
In addition to their effects on bone, Twist family members are
major regulators of epithelial-to-mesenchymal transition (EMT)
during development and carcinogenesis. EMT is a process by which
epithelial cells lose their polarity and are converted to a
mesenchymal phenotype. One of the characteristic ﬁndings in
EMT is loss of E-cadherin expression leading to tumor progression,
metastasis, and poor prognosis in various human carcinomas; one
possible mechanism involved in Twist-mediated EMT is repression
of E-cadherin [Yang et al., 2004a]. An intriguing recent ﬁnding also
identiﬁes ATF4 as required for regulation of EMT [Suzuki et al.,
2010] in the context of neural crest development. The role of ATF4 in
carcinogenesis and the regulation of EMT by Twist and ATF4 are
topics of future studies in our laboratory. PTHrP is produced by a
majority of tumors that metastasize to bone and its expression
correlates with skeletal localization of tumors [Liao and McCauley,
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2006]. A recent study has implicated PTHrP in EMT contributing to
renal ﬁbosis [Ardura et al., 2010]. Whether PTHrP plays a role during
tumor-associated EMT and how PTHrP affects essential regulators of
EMT such as Twist1, is currently unknown.
In conclusion, this study provides the ﬁrst evidence that Twist1
and Twist2 modulate ATF4-dependent transcriptional activity in
response to PTH. Further studies aimed at identifying how PTH
regulates Twist transcription will improve our understanding of how
this hormone controls osteoblasts and bone remodeling.
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